首页> 外文期刊>Korean journal of radiology : >Contrast-Enhanced CT with Knowledge-Based Iterative Model Reconstruction for the Evaluation of Parotid Gland Tumors: A Feasibility Study
【24h】

Contrast-Enhanced CT with Knowledge-Based Iterative Model Reconstruction for the Evaluation of Parotid Gland Tumors: A Feasibility Study

机译:对比增强CT与基于知识的迭代模型重建在腮腺肿瘤评估中的可行性研究

获取原文
获取外文期刊封面目录资料

摘要

Objective The purpose of this study was to determine the diagnostic utility of low-dose CT with knowledge-based iterative model reconstruction (IMR) for the evaluation of parotid gland tumors. Materials and Methods This prospective study included 42 consecutive patients who had undergone low-dose contrast-enhanced CT for the evaluation of suspected parotid gland tumors. Prior or subsequent non-low-dose CT scans within 12 months were available in 10 of the participants. Background noise (BN), signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) were compared between non-low-dose CT images and images generated using filtered back projection (FBP), hybrid iterative reconstruction (iDose4; Philips Healthcare), and knowledge-based IMR. Subjective image quality was rated by two radiologists using five-point grading scales to assess the overall image quality, delineation of lesion contour, image sharpness, and noise. Results With the IMR algorithm, background noise (IMR, 4.24 ± 3.77; iDose4, 8.77 ± 3.85; FBP, 11.73 ± 4.06; p = 0.037 [IMR vs. iDose4] and p 4, 10.20 ± 3.29; FBP, 7.33 ± 2.03; p = 0.011 [IMR vs. iDose4] and p Conclusion Iterative model reconstruction-generated low-dose CT is an alternative to standard non-low-dose CT without significantly affecting image quality for the evaluation of parotid gland tumors.
机译:目的本研究的目的是确定基于知识的迭代模型重建(IMR)的低剂量CT在腮腺肿瘤评估中的诊断作用。资料和方法这项前瞻性研究包括42例接受低剂量对比增强CT检查的连续患者,以评估可疑的腮腺肿瘤。 10名参与者可在12个月内进行先前或随后的非低剂量CT扫描。比较非低剂量CT图像和使用滤波反投影(FBP)生成的图像,混合迭代重建的背景噪声(BN),信噪比(SNR)和对比度噪声比(CNR) (iDose 4 ; Philips Healthcare)和基于知识的IMR。两位放射线医师使用五点分级量表对主观图像质量进行了评估,以评估整体图像质量,病变轮廓的轮廓,图像清晰度和噪声。结果使用IMR算法,背景噪声(IMR,4.24±3.77; iDose 4 ,8.77±3.85; FBP,11.73±4.06; p = 0.037 [IMR与iDose 4 ]和p 4 ,10.20±3.29; FBP,7.33±2.03; p = 0.011 [IMR与iDose 4 ]和p结论结论迭代模型重建生成的低剂量CT为一种标准的非低剂量CT替代方案,而不会显着影响腮腺肿瘤的评估图像质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号